Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells
Ovarian cancer is the most lethal gynecologic malignancy due to the tumor's acquisition of chemoresistance to platinum-based chemotherapy. To solve this problem, we conducted RNAi-based large-scale screening and determined that tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) is a key molecule involved in the platinum resistance of ovarian cancer cells. Recently, a variety of studies have investigated that small extracellular vesicles (sEVs) contribute to the communication between cancer cells, including the development of chemoresistance in ovarian cancer. The purpose of our study is to determine if sEVs-derived TIE-1 is involved in the chemoresistance of ovarian cancer cells. TIE-1-overexpressed TOV112D cells, termed TOV112D TIE-1 was contained within sEV Our findings suggest that sEV-derived TIE-1 could be a new therapeutic target for refractory ovarian cancer.